Ovid Therapeutics (NASDAQ:OVID – Get Rating) and Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Ovid Therapeutics and Ultragenyx Pharmaceutical’s net […]
Equities analysts expect that Ovid Therapeutics Inc. (NASDAQ:OVID – Get Rating) will announce earnings per share (EPS) of ($0.23) for the current quarter, Zacks reports. Zero analysts have issued estimates for Ovid Therapeutics’ earnings. Ovid Therapeutics also reported earnings per share of ($0.23) in the same quarter last year. The business is expected to issue […]
Ovid Therapeutics (NASDAQ:OVID – Get Rating) had its price target decreased by investment analysts at Citigroup to $2.40 in a research note issued on Friday, Stock Target Advisor reports. The brokerage currently has a “neutral” rating on the stock. Citigroup’s price target suggests a potential upside of 16.50% from the company’s current price. Separately, Zacks […]
Form 8-K Ovid Therapeutics Inc For: May 10 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in.